Literature DB >> 16393693

Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines.

Islay A Steele1, Richard J Edmondson, Hing Y Leung, Barry R Davies.   

Abstract

Epithelial ovarian cancer (EOC) is the most common and lethal form of gynecological malignancy. These cancers are thought to be derived from the ovarian surface epithelium (OSE). We have previously reported that the epithelial-specific FGF receptor 2 splice variant IIIb is not expressed in normal OSE, but is expressed in approximately 80% of EOCs. We have examined the phenotypic effects of ligands to FGF receptor 2-IIIb, namely FGFs 1,7 and 10, on a panel of EOC cell lines. We show that these ligands increase cell viability, induce DNA synthesis, motility and chemotaxis and protect from spontaneous cell death when EOC cells are maintained in serum free medium. A blocking antiserum to FGF-7 reduces viability of 41-M EOC cells, and abrogates the ability of ascitic fluid containing FGF-7 to induce DNA synthesis in these cells. Finally, we show that FGF-7 can induce a reorganization of the actin cytoskeleton in SK-OV-3 ovarian cancer cells. It is suggested that ligands to FGF receptor 2-IIIb affect a range of phenotypes important in the neoplastic growth of EOCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393693     DOI: 10.1080/08977190500361697

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  10 in total

1.  Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts.

Authors:  Wei-meng Zhao; Lihong Wang; Hangil Park; Sophea Chhim; Melanie Tanphanich; Masakazu Yashiro; K Jin Kim
Journal:  Clin Cancer Res       Date:  2010-07-29       Impact factor: 12.531

2.  Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Authors:  Claire Cole; Sin Lau; Alison Backen; Andrew Clamp; Graham Rushton; Caroline Dive; Cassandra Hodgkinson; Rhona McVey; Henry Kitchener; Gordon C Jayson
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

3.  Keratinocyte growth factor enhances barrier function without altering claudin expression in primary alveolar epithelial cells.

Authors:  Michael J LaFemina; Deepti Rokkam; Anita Chandrasena; Jue Pan; Anisha Bajaj; Meshell Johnson; James A Frank
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-10       Impact factor: 5.464

4.  Tissue-specific roles of Fgfr2 in development of the external genitalia.

Authors:  Marissa L Gredler; Ashley W Seifert; Martin J Cohn
Journal:  Development       Date:  2015-06-15       Impact factor: 6.868

5.  Induction of neuro-protective/regenerative genes in stem cells infiltrating post-ischemic brain tissue.

Authors:  Gokhan Yilmaz; J Steven Alexander; Cigdem Erkuran Yilmaz; D Neil Granger
Journal:  Exp Transl Stroke Med       Date:  2010-05-28

6.  Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.

Authors:  Margaret A Gates; Shelley S Tworoger; Kathryn L Terry; Immaculata De Vivo; David J Hunter; Susan E Hankinson; Daniel W Cramer
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

7.  Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.

Authors:  Qing H Meng; Enping Xu; Michelle A T Hildebrandt; Dong Liang; Karen Lu; Yuanqing Ye; Elizabeth A Wagar; Xifeng Wu
Journal:  Clin Chem       Date:  2013-10-21       Impact factor: 8.327

8.  Expression and clinical significance of fibroblast growth factor 1 in gastric adenocarcinoma.

Authors:  Naiqing Liu; Jingyu Zhang; Shuxiang Sun; Liguang Yang; Zhongjin Zhou; Qinli Sun; Jun Niu
Journal:  Onco Targets Ther       Date:  2015-03-09       Impact factor: 4.147

Review 9.  Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

Authors:  Nikos G Gavalas; Michalis Liontos; Sofia-Paraskevi Trachana; Tina Bagratuni; Calliope Arapinis; Christine Liacos; Meletios A Dimopoulos; Aristotle Bamias
Journal:  Int J Mol Sci       Date:  2013-07-30       Impact factor: 5.923

10.  Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.

Authors:  Petra E A Huijts; Maaike P G Vreeswijk; Karin H G Kroeze-Jansema; Catharina E Jacobi; Caroline Seynaeve; Elly M M Krol-Warmerdam; Pauline M Wijers-Koster; Jannet C Blom; Karen A Pooley; Jan G M Klijn; Rob A E M Tollenaar; Peter Devilee; Christi J van Asperen
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.